Literature DB >> 3390830

Genetic instability and the development of steroid hormone insensitivity in cultured T 47D human breast cancer cells.

R R Reddel1, I E Alexander, M Koga, J Shine, R L Sutherland.   

Abstract

The estrogen receptor (ER)-positive human breast cancer cell line T 47D exhibited genetic instability under cell culture conditions which maintained almost continuous exponential growth. This resulted in the spontaneous generation of three ER-positive sublines with a range of DNA ploidies and distinctive phenotypes. One of these sublines, T 47D-5, exhibited resistance to the growth-inhibitory effects of the synthetic nonsteroidal antiestrogen tamoxifen and the synthetic progestin ORG 2058, in marked contrast to "wild type" T 47D cells (designated T 47D-7 in this study). T 47D-5 cells were cloned by limiting dilution and 11 clonal cell lines were tested for sensitivity to tamoxifen. Although all clones of T 47D-5 were significantly less sensitive than T 47D-7 cells, a spectrum of sensitivities was observed. Three clones, T 47D-5-13, T 47D-5-21, and T 47D-5-23, were further characterized by measuring the concentrations of receptors for estrogen, progesterone, growth hormone, and epidermal growth factor and responses to estradiol, tamoxifen, and progestin, in terms of both induction of specific proteins and effects on cellular proliferation. Although the T 47D-5 subline and clone T 47D-5-23 were insensitive to both the growth-stimulatory effects of estradiol and the inhibitory effects of tamoxifen, this was not related to the concentration of ER or its ability to induce progesterone receptor. Estrogen receptor levels were similar in resistant and sensitive clones of T 47D-5 [70,000-81,000 sites/cell] and were 2.5-fold greater than in the sensitive T 47D-7 line [32,600 +/- 5,000 (SEM) sites/cell]. Northern blots showed no difference in the size of ER mRNA transcripts between sensitive and resistant clones. Estradiol treatment increased progesterone receptor (PR) levels in all cell lines but the magnitude and sensitivity of this response were unrelated to growth responses indicating a divergence in estrogenic control of cellular proliferation and specific protein synthesis within these clones. T 47D-5, T 47D-5-13, T 47D-5-21, and T 47D-5-23 were all insensitive to the growth-inhibitory effects of ORG 2058. The progestin was also unable to increase lactogenic and epidermal growth factor receptor concentrations in these four lines in contrast to the response in T 47D-7 cells. The insensitivity to progestin in the T 47D-5 subline and its three clonal cell lines could be accounted for, in part, by a 75-80% reduction in PR levels when compared with T 47D-7 cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3390830

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.

Authors:  E A Musgrove; C S Lee; R L Sutherland
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

2.  Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.

Authors:  G Bernhardt; H Reile; H Birnböck; T Spruss; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells.

Authors:  C Hurd; K Nag; N Khattree; P Alban; S Dinda; V K Moudgil
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

4.  BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype.

Authors:  Crystal N Marconett; Travis J Morgenstern; Adrianna K San Roman; Shyam N Sundar; Ankur K Singhal; Gary L Firestone
Journal:  Cancer Biol Ther       Date:  2010-08-20       Impact factor: 4.742

Review 5.  The role of estrogen receptors in breast cancer metastasis.

Authors:  S A Fuqua
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

6.  Immunobead filtration: a novel approach for the isolation and propagation of tumor cells.

Authors:  P D Rye; H K Høifødt; G E Overli; O Fodstad
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

7.  Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.

Authors:  J E Macheledt; A U Buzdar; G N Hortobagyi; D K Frye; J U Gutterman; F A Holmes
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

8.  Microenvironment and endocrine resistance in breast cancer: Friend or foe?

Authors:  Sol Recouvreux; Rocío Sampayo; María Inés Díaz Bessone; Marina Simian
Journal:  World J Clin Oncol       Date:  2015-12-10

9.  Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo.

Authors:  Danielle Meijer; Hans Gelderblom; Marcel Karperien; Anne-Marie Cleton-Jansen; Pancras C W Hogendoorn; Judith V M G Bovee
Journal:  Clin Sarcoma Res       Date:  2011-07-25

10.  High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.

Authors:  H W van den Berg; J Martin; M Lynch
Journal:  Br J Cancer       Date:  1990-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.